Created

Sep 12, 2023 6:57 PM

Type

patent

Publication

Summary

This is a patent for stabilized hypohalous acid solutions, which are used for disinfection and treatment of various conditions, and the patent includes detailed information about the formulation and use of the solutions.

Key Points

- The patent discusses stabilized hypohalous acid solutions and their potential applications in medicine, specifically for treating dermatological disorders, wounds, ulcers, burns, scars, keloids, and bacterial infections. - The patent also mentions the use of hypochlorous acid as an antibacterial agent and local antiseptic. - The document lists several other patents and publications related to the use of hypochlorous acid and other oxidizing agents in various applications, including wound healing, water purification, and dental care.

super:Link

https://patents.google.com/patent/US10576152B2/en?q=(stabilizing+HOCl)&oq=stabilizing+HOCl

Date

Notes

Attachment

Source

This is from US Patent in 2020 at https://patents.google.com/patent/US10576152B2/en?q=(stabilizing+HOCl)&oq=stabilizing+HOCl

Keywords

Top five keywords: stabilized hypohalous acid solutions, patent, Urgo US Inc, Svetlana Panicheva, Mark N. Sampson.

Stabilized hypohalous acid solutions Download PDF

Info

Publication number US10576152B2 US16/018,306 US201816018306A US10576152B2 US 10576152 B2 US10576152 B2 US 10576152B2 US 201816018306 A US201816018306 A US 201816018306A US 10576152 B2 US10576152 B2 US 10576152B2 Authority Prior art keywords Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active

Application number

Other versions

Inventor

Svetlana Panicheva

Mark N. Sampson

Gerald N. DiBello

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Urgo US Inc

Original Assignee

Urgo US Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Filing date

Publication date

Priority claimed from US201161454383P external-priority

2018-06-26 Application filed by Urgo US Inc filed Critical Urgo US Inc

2018-06-26 Priority to US16/018,306 priority Critical patent/US10576152B2/en

2019-01-31 Assigned to REALM THERAPEUTICS, INC. reassignment REALM THERAPEUTICS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PURICORE, INC.

2019-05-23 Publication of US20190151449A1 publication Critical patent/US20190151449A1/en

2019-06-07 Assigned to URGO US, INC. reassignment URGO US, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REALM THERAPEUTICS, INC.

2020-01-08 Priority to US16/737,671 priority patent/US11452778B2/en

2020-03-03 Application granted granted Critical

2020-03-03 Publication of US10576152B2 publication Critical patent/US10576152B2/en

Status Active legal-status Critical Current

2032-03-19 Anticipated expiration legal-status Critical

Images

Classifications

A—HUMAN NECESSITIES
A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/02—Inorganic compounds

A—HUMAN NECESSITIES
A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
A01N2300/00—Combinations or mixtures of active ingredients covered by classes A01N27/00 - A01N65/48 with other active or formulation relevant ingredients, e.g. specific carrier materials or surfactants, covered by classes A01N25/00 - A01N65/48

A—HUMAN NECESSITIES
A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N25/22—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients

A—HUMAN NECESSITIES
A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
A23L3/358—Inorganic compounds

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
A61K33/10—Carbonates; Bicarbonates

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
A61K33/12—Magnesium silicate

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/42—Phosphorus; Compounds thereof

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders
A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/02—Local antiseptics

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/04—Antibacterial agents

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P37/00—Drugs for immunological or allergic disorders
A61P37/08—Antiallergic agents

C—CHEMISTRY; METALLURGY
C01—INORGANIC CHEMISTRY
C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
C01B11/00—Oxides or oxyacids of halogens; Salts thereof
C01B11/04—Hypochlorous acid

Abstract

The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing surfaces, or treating and/or preserving food products and cut flowers, among other uses.

Description

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/184,207 filed Jun. 16, 2016 (U.S. Pat. No. 10,034,942), which is a continuation of U.S. patent application Ser. No. 14/501,977 filed Sep. 30, 2014 (U.S. Pat. No. 9,392,787), which is a continuation of U.S. patent application Ser. No. 13/423,822 filed Mar. 19, 2012 (U.S. Pat. No. 8,871,278), which claims the benefit of, and priority to, U.S. Provisional Application No. 61/454,383, filed Mar. 18, 2011, and U.S. Provisional Application No. 61/526,149, filed Aug. 22, 2011, each of which are hereby incorporated by reference in their entirety.

TECHNICAL FIELD

The present invention relates to stabilized solutions and formulations of hypohalous acid, such as hypochlorous acid (HOCl), as well as methods for their production and use. The solution finds use for cleaning and/or disinfecting surfaces, food such as fruit, vegetables and crops, or mammalian tissues (including wounds). The solutions further find use in the preservation of agricultural products and cut flowers.

BACKGROUND

Hypochlorous acid is an oxidant and biocide that is produced by the human body's natural immune system to fight infection. Hypochlorous acid is generated as the final step of the Oxidative Burst Pathway, with large quantities of hypochlorous acid being released into the phagocytic vesicles to destroy the invading microorganisms. It is considered that hypochlorous acid exerts its biocidal effect by attacking the surface and plasma membrane proteins, impairing transport of solutes and the salt balance of bacterial cells (Pieterson et al., Water SA, 22(1): 43-48 (1996)). Escherichia coli exposed to hypochlorous acid lose viability in less than 100 ms due to inactivation of many vital systems. (Fair et al., 40 J. Am. Water Works Assoc. 1051-61 (1940)). Hypochlorous acid at 2.6 ppm caused 100% growth inhibition of E. coli in dilute bacterial suspensions in about 5 minutes. (Chesney et al., 178 J. Bacteria 2131-2135 (1996)). According to Chemistry of Water Treatment (2nd Edition), S. D. Faust and O. M. Aly (1998), 100% kill in 5 minutes requires only 0.08 ppm for A. aerogenes, 0.06 ppm for S. typhosa, 0.05 ppm for S. dysenteriae, and 0.03 ppm for E. coli.

Hypohalous acid has a wide range of applications where it is important to control microbial contamination, such as for the care and management of wounds, disinfecting hard surfaces such as medical or dental equipment, food safety and processing, water treatment, as well as other industrial and agricultural applications.

One limitation associated with solutions of hypochlorous acid is their stability, which has limited much of the commercial use to those situations where the solution can be made on site for relatively immediate use. Existing alternatives include Dakin's solution for wound care, which is a diluted sodium hypochlorite solution (0.5%) prepared by mixing sodium hypochlorite (5.25%), sodium bicarbonate/carbonate (1%), and clean tap water. However, Dakin's solution has a high pH, and thus causes pain and burning in wound treatment along with rashes, itching, swelling, hives, and/or blisters. Further, Dakin's solution is unstable and unsuited for clinical use at lower pH's (<8.5). Another alternative is the Microcyn™ solution. While Microcyn has a 2 year shelf life, it suffers from a limited level of available free chlorine (AFC) of about 80 ppm (pH of 7.4), and lower percent of hypochlorous acid, which may limit its biocidal effectiveness. EcaFlo™ is available for hard surface disinfection. This solution contains equimolar amounts of hypochlorite and hypochlorous acid in addition to high sodium chloride content. The pH of the solution is around 7.5 and the solution has an AFC content of approximately 460 ppm. The solution has a relatively short shelf life of 30 days.

There is an unmet need for a hypohalous acid solution that has a high AFC content, has sufficient stability and/or other properties required to be commercially useful in medical and other commercial settings, and is not irritating or harmful to humans. The claimed invention meets these and other objectives.

SUMMARY OF THE INVENTION

The present invention provides a stabilized hypohalous acid solution or formulation thereof, which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution or formulation thereof, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing hard surfaces, treating (e.g., preserving and/or disinfecting) food products or cut flowers, among other uses.

In one aspect, the invention provides a stabilized hypohalous acid solution. The solution incorporates a stabilizing amount of dissolved inorganic carbon (DIC), which can be in the form of a bicarbonate or carbonate of an alkali or alkaline earth metal. The solution may have an available free chlorine (AFC) content of from about 10 to about 10,000 parts per million, and a pH of from about 4.0 to about 7.5. For example, in certain embodiments, the solution has a pH of from about 5 to about 7. In certain embodiments, the solution contains hypochlorous acid, and is prepared by electrolysis of saline. The solution is stabilized, as determined by its change in pH and/or AFC over time, for at least one month, but in various embodiments, the solution is stabilized for at least six months, at least one year, or more.

In certain embodiments, sodium bicarbonate is incorporated into the solution at a level of about 5:1 to about 1:5 molar ratio relative to the AFC content. For example, sodium bicarbonate may be added at a level of about 1:1, about 1:2, or about 1:3 or at a larger (i.e., more dilute) molar ratio relative to the AFC content (e.g., the hypohalous acid content). In certain embodiment, sodium bicarbonate is incorporated into the solution at a level of about 1:1 to about 1:2, relative to the AFC content. While the solution may contain phosphate buffers in some embodiments, in other embodiments, the solution does not contain, or contains only limited, phosphate buffer. For example, the solution may comprise HOCl produced by electrolysis of saline, and the solution may have an AFC content of from about 100 to about 500 parts per million, a pH in the range of about 5 to about 7, a salinity of about 0.02% to about 1.0%, and an amount of dissolved inorganic carbon in the range of about 300 mg/L to about 1500 mg/L. In some embodiments, the salinity of the solution does not impact the amount of bicarbonate needed for solution stabilization. In certain embodiments, the HOCl solution is formulated as a hydrogel.

In another aspect, the invention provides a method for preparing the stabilized hypohalous acid solution. The method involves incorporating the DIC (e.g., in the form of carbonate or bicarbonate) by addition to an electrolyte for electrochemical treatment, or incorporating the DIC (e.g., in the form of carbonate or bicarbonate) by directly adding to an electrolyzed solution comprising hypohalous acid (e.g., HOCl).

Still other aspects of the invention provide methods of disinfecting, cleansing, or treating a mammalian tissue, such as a wound, burn, or dermatosis, or provides methods of sanitizing, disinfecting or cleansing a hard surface, or provides methods for treating or preserving a food or agricultural product or cut flowers. Due to the stability of the hypohalous acid solutions and formulations, such methods need not be performed proximately to the production of the biocidal solution. Further, as shown herein, stabilized hypohalous acid solutions of the invention maintain activity even in the presence of high organic load. In still other embodiments, the invention provides a method for treating a skin condition, including dermatosis, rosasea, skin infection, skin allergy, psoriasis, or acne. In such embodiments, the HOCl may be formulated as a hydrogel.

DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B show the change in pH over time of an HOCl solution stored at room temperature (FIG. 1A) or stored at less than 20° C. (FIG. 1B).

FIGS. 2A and 2B show the change in AFC over time of an HOCl solution stored at room temperature (FIG. 2A) or stored at less than 20° C. (FIG. 2B).

FIG. 3 shows the AFC drop over storage time in bottled HOCl solutions containing bicarbonate (“non-buffered”), or with bicarbonate and phosphate buffer.

FIG. 4 shows the change in pH and AFC of the bicarbonate-containing HOCl solutions without phosphate buffer.

FIG. 5 shows the reduction in C. difficile spores in the presence of high organic load. The solutions tested are as follows: pH 6.7, AFC of 250 ppm, NaHCO3 at 400 mg/L; pH 6.7, AFC of 480 mg/L, 0.0 NaHCO3; and pH 6.3, AFC of 480 ppm, and NaHCO3 at 1000 mg/L.

FIG. 6 shows the results of an extended stability study of HOCl produced by electrochemical treatment of NaHCO3-enriched NaCl solution at targeted pH 5.4, bottled in a polyethylene terephthalate (PET) container and stored at room temperature.

FIGS. 7A and 7B show the stability of HOCl added to containers comprising dry sodium bicarbonate. FIG. 7A shows stability of pH. FIG. 7B shows stability of AFC content.

FIG. 8 shows the effect of bicarbonate on pH and solution stability in hypochlorous acid solutions having a targeted pH for agricultural applications.

DETAILED DESCRIPTION

The present invention provides a stabilized hypohalous acid solution or formulation thereof, which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing surfaces, or treating or preserving food products or cut flowers, among other uses.

In one aspect, the invention provides a stabilized hypohalous acid solution or formulation thereof. The solution incorporates a stabilizing amount of dissolved inorganic carbon (DIC), such as a bicarbonate or carbonate of an alkali or alkaline earth metal. The solution may have an available free chlorine (AFC) content of from about 10 to about 10,000 parts per million, and a pH of from about 4.0 to about 7.5. In certain embodiments, the solution contains hypochlorous acid, and is prepared by electrolysis of saline. The solution is stabilized, as determined by its change in pH and/or AFC over time, for at least one month, but in various embodiments, the solution is stabilized for at least six months, at least one year, or more.

The hypohalous acid solution may be generated by electrolysis of a halide salt, such as sodium chloride, and may comprise a mixture of oxidizing species such as predominantly hypochlorous acid and sodium hypochlorite. Hypochlorous acid and hypochlorite are in equilibrium and the position of the equilibrium is determined predominately by the pH (that is, pH effects the concentration of each component). An electrolyzed sodium chloride solution with a pH of 5.1 to 6.0 has a purity of about ≥95% hypochlorous acid. Thus, the electrolyzed solution supplied may have a pH of from about 4.0 to about 7.5, but in certain embodiments has a pH of from about 4.4 to about 7.0, or a pH of about 5 to about 7, or a pH of from about 5.4 to about 6.4, or a pH of from about 5.0 to about 6.4. At a pH of about 5.4 the solution will contain mostly (close to 100%) hypochlorous acid with respect to hypochlorite.

While the solution may comprise, or consist essentially of hypochlorous acid as the active agent, in some embodiments, it may contain other hypohalous acids (e.g., HOBr, or mixture thereof). In some embodiments, the solution contains other oxidizing or radical producing species such as a hypohalite (e.g., hypochlorite), hydroxide, H2O2 and O3, among others.

The biocidal activity of the solution can be expressed in terms of available free chlorine or AFC. While the invention is applicable to an AFC range of from about 10 to about 10,000 ppm (or to about 5000 ppm), in certain embodiments, the solution has a relatively high AFC content and is suitable for use with mammalian tissues or agricultural products. For example, the solution may have an AFC content of from about 100 to 1000 ppm, or 100 to 500 ppm, or about 150 to about 250 ppm. Other AFC levels may be employed, and may be selected based upon the intended application. For example, without any limitation, for surface disinfection the AFC may be in the range of about 140 to about 2000 ppm, or about 400 to about 1000 ppm.

While the hypochlorous acid may be produced chemically in accordance with some embodiments (e.g., by acidification of hypochlorite), the hypohalous acid may also be produced electrochemically. The electrochemical production of hypohalous acid is by treatment of halide-based electrolytes in a diaphragm-type electrolytic cell. Electrochemical treatment of saline is described, for example, in U.S. Pat. Nos. 7,303,660, 7,828,942, and 7,897,023, which are hereby incorporated by reference in their entireties.

The solution employs a stabilizing amount of DIC, which may be a bicarbonate or carbonate of alkali or alkaline earth metal, such as, for example, sodium, potassium, calcium, or magnesium. In some embodiments, the bicarbonates or carbonates are added prior to the formation of hypohalous acid (e.g., by electrochemical treatment), and in other embodiments, the bicarbonates or carbonates are added to the solution after formation of hypohalous acid. For example, the bicarbonate(s) or carbonate(s) may be added to the precursor solution, the electrolyte, and/or the end solution.

The DIC is incorporated at a “stabilizing amount,” which can be determined with reference to the change in the pH or AFC content of the solution over time. Generally, the solution is considered stabilized if the amount of AFC does not drop below about 75% of the initial value over a period of about 6 months. In certain embodiments, the AFC content is stabilized for at least one year from the production date of the solution. Further, the stability of the solution may be determined with reference to the pH. Generally, the solution is considered stabilized if the pH does not vary by 1 unit over a period of about 6 months. In certain embodiments, the pH is stabilized for at least one year from the production date of the solution. The solution should be stored at 25° C. or at 20° C. or less for greater stability. 25° C. and 20° C. are the reference temperatures for determination of stability. For stability testing, solutions are packaged in HDPE bottles, stored in the dark, and kept unopened.

The stabilizing amount of DIC (e.g. as added carbonate or bicarbonate) can be determined with reference to the AFC content. For example, in certain embodiments, the stabilizing amount of the carbonate or bicarbonate is incorporated into the solution at a molar ratio of from about 5:1 to 1:5 with respect to the AFC level. In some embodiments, the bicarbonates or carbonates are incorporated into the solution in at least equimolar amounts with respect to the AFC content (e.g., hypochlorous acid content). In still other embodiments, the DIC (e.g., bicarbonate or carbonate) is incorporated at about 5:1, about 2:1, about 1:1, about 1:2, about 1:3, or about 1:5 with respect to AFC content. In various embodiments, other buffering components such as phosphate buffers, are not employed, or are minimally employed. For example, for solutions having an AFC content of from about 200 ppm to about 500 ppm, carbonate or bicarbonate may be incorporated at an amount of from about 300 mg/L to about 1500 mg/L to stabilize the solution. In certain embodiments, such solutions are stabilized by incorporating from about 400 to about 1000 mg/L of carbonate or bicarbonate.

Without being bound by theory, dissolved inorganic carbon (DIC), which generally includes carbonates, bicarbonates, carbonic acid and dissolved CO2, provides low or minimal buffering capacity in the pH range targeted by the solutions and compositions described herein. Nevertheless, these solutions are effectively stabilized, such that the solutions and compositions are not dependent on “on-demand” production. The stabilizing effect can be due to, in-part, free radical scavenging ability of DIC to thereby slow the decomposition of HOCl. Further still, solutions prepared by electrochemical treatment of bicarbonate-enriched sodium chloride solution (as opposed to chemical acidification of sodium hypochlorite stabilized with equal amount of carbonate/bicarbonate), have distinct properties with respect to DIC, and the stabilizing effect can be distinct.

In some embodiments, as shown in FIG. 5, the addition of the bicarbonates or carbonates of alkali or alkaline earth metals provides enhanced biocidal effectiveness for treating microorganism or biofilms, especially in the presence of high organic load.

While the hypohalous acid solution may be in the form of a liquid, the solution may take the form of a cream, gel (e.g. silicon-based gel), and/or foam by the addition of conventional ingredients known in the art. For example, topical formulations of electrochemical solutions are disclosed in US 2005/0196462, which is hereby incorporated by reference in its entirety. In these embodiments, the formulation is better contained around the application site by limiting solution run-off. Further, convenient applicators for creams, foams, and the like are known, and may be used in accordance with the present invention. Since the solutions of the invention provide the potential for low conductivity, even with relatively high AFC content, and at “skin-friendly” pH levels, the solutions of the invention are particularly suitable for hydrogel formulations.

In certain embodiments employing hydrogel formulations, the composition has an AFC content of greater than about 100 ppm, greater than about 150 ppm, greater than about 200 ppm, greater than about 250 ppm, or greater than about 300 ppm. Further, the formulation may have a viscosity of from about 0.5 mS/cm to about 12 mS/cm, such as from about 1 mS/cm to about 10 mS/cm in some embodiments. Further, hydrogel formulations in some embodiments have a pH of from about 5 to about 7, or from about 5 to about 6.5 in other embodiments. The hydrogels may be prepared from silicate-based carriers, such as sodium magnesium fluorosilicate (e.g., from about 0.5% to about 5%), and may employ an additional buffer for targeting the pH. An exemplary buffer is phosphoric acid.

The stabilized solutions may be packaged for storage or sale, using any suitable container, such as any suitable plastic or glass bottles, or bags (e.g., plastic bags), tubes, or cans (e.g., spray or aerosol). In certain embodiments, the packaging material has minimal gas permeability, including by species such as CO2 and O2. The containers may be transparent, or opaque so that they are impenetrable by light, and may be of any unit volume, such as about 100 ml, about 125 ml, about 250 ml, about 0.5 liter, about 1 liter, about 5 liters, about 10 liters, or greater.

The hypochlorous acid solution of the invention may also be hypertonic, hypotonic, or isotonic with respect to physiological fluids (blood, plasma, tears, etc.). Alternatively, the solution may contain varying levels of salinity, such as from 0.01 to about 2.0%. Generally, the solution contains from about 0.02% to about 0.9% w/v NaCl when intended for use in medicine. In some embodiments, the solution may be a normal saline solution (about 0.9% w/v NaCl). In some embodiments, the solution may contain from about 0.01 to 2.0% w/v one or more salts, such as a halide salt, e.g. NaCl, KCl, or a mixture of salts or halide salts. The salt, or halide salt may be a salt of an alkali metal or alkaline earth metal, such as sodium, potassium, calcium, or magnesium. In certain embodiments, the electrolyzed solution is generated using a mixture of physiologically balanced salts, as disclosed in U.S. Pat. No. 6,426,066, which is hereby incorporated by reference in its entirety. Such salts may include potassium halides (e.g., KCl) and magnesium halides (e.g., MgCl2).

In another aspect, the invention provides a method for preparing the stabilized hypohalous acid solution. The method involves incorporating the carbonate or bicarbonate into an electrolyte for electrochemical treatment, or directly to an electrolyzed solution comprising hypohalous acid (e.g., HOCl).

For example, an electrolyzed solution or other hypohalous acid solution may be diluted with water or aqueous solution comprising bicarbonates or carbonates. In other embodiments, the diluted hypohalous acid solution (e.g., having the desired AFC content) is added to containers comprising dry bicarbonates or carbonates of alkali or alkaline earth metals. The latter is an effective method for production of low ionic strength hypohalous acid solutions, especially for hydrogel formulations.

The stabilized hypochlorous acid solutions (e.g. solutions of greater than 90%, 95%, or 97% HOCl) may be obtained by electrolysis of a saline solution as described in U.S. Pat. No. 7,276,255, which is hereby incorporated by reference in its entirety, or can be prepared by any suitable method or apparatus, by incorporating the bicarbonate or carbonate into the dry electrolyte or the solution for electrolysis. The carbonate or bicarbonate can be added to the dry electrolyte in accordance with the desired AFC content of the resulting solution, as described in detail herein. Hypochlorous acid solutions may be prepared by passing saline solution containing the carbonate/bicarbonate over coated titanium electrodes separated by a semi-permeable ceramic membrane at a current of about 6 to 9 Amps. Electrochemical treatment of saline is described, for example, in U.S. Pat. Nos. 7,303,660, 7,828,942, and 7,897,023, which are hereby incorporated by reference.

Still other aspects of the invention provide methods of disinfecting or cleansing a mammalian tissue, such as a wound or burn, or disinfecting or cleansing a hard surface, or for treating or preserving a food product or cut flowers. Due to the stability of the hypohalous acid solutions, such methods need not be performed proximately to the production of the biocidal solution, and the solution may be prepared well in advance of its use.

The solutions and formulations of the invention may be used as a sterilizing, disinfecting and biocidal solution for human and animal care. The solutions are non-hazardous, non-irritating, non-sensitizing to the skin, non-irritating to the eyes, not harmful if swallowed, and show no evidence of mutagenic activity. For example, the method of the invention provides for moistening, lubricating, irrigating, cleaning, deodorizing, disinfecting, or debriding a wound by rinsing, washing or immersing the wound, with or in, the stabilized or stored hypohalous acid solutions, or by applying the solution to the wound and/or wound dressing. The wound may or may not be infected, and thus the method of the invention is useful for treating infected wounds and useful for preventing infection of uninfected wounds.

In one aspect, the invention provides a convenient means for wound care and management and may be used in combination with the apparatus and methods described in U.S. 2010/030132, which is hereby incorporated by reference in its entirety. For example, the method may comprise supplying the stabilized solution to a wound site by one or more of soak, scrub, pulsed lavage, hydrosurgery, and ultrasound to effectively debride and disinfect a wound or tissue. The solution may be delivered before, during and/or after negative pressure wound therapy to promote proper wound healing physiology. In these embodiments, the method may employ a wound dressing for coordinating debridement by infusion of hypochlorous acid with negative pressure therapy. Thus, the invention may be used in combination with a wound treatment apparatus and/or wound dressing.

For example, in certain embodiments, the invention allows for an initial stabilized hypochlorous acid solution soak and/or scrub to both debride and disinfect the wound or tissue, followed by the application of negative pressure to the wound or tissue (as described herein) using the stabilized hypochlorous acid solution as an irrigant to control wound bioburden, remove excess exudate, and promote formation of granulation tissue. Optionally, the method also involves seamless transition to the stabilized hypohalous acid solution infusion (e.g., active or passive infusion without negative pressure). Such seamless transition can be effected via a wound dressing which allows for controlled infusion of stabilized hypochlorous acid solution with controlled vacuum source. In these embodiment, continued cell proliferation and regeneration continues without disruption of the wound bed, once the endpoints of negative pressure therapy have been obtained.

In certain embodiments of the invention, the wound needing care is a stage I-IV pressure ulcer, stasis ulcer, diabetic ulcer, post-surgical wound, burn, cut, abrasion, or a minor irritation of the skin. In certain embodiments, the wound is rinsed, washed, or immersed in the solution periodically over at least two weeks, but treatment may continue periodically for over about 4 weeks, about 9 weeks, or more. The wound, in some embodiments, is rinsed with the solution at least once a week, but may be treated with the solution at least twice a week, or more frequently.

While the hypohalous acid solution may be delivered to the wound at room temperature, the solution may alternatively be heated, for example, to body temperature or about body temperature. In this embodiment, the solution is comfortable and soothing for the patient, and is more effective.

In some embodiments, the invention provides a method for treating an infected or colonized wound, tissue, surgical cavity, or bone, and a method for reducing wound bioburden. The treatment solution in accordance with the invention, as already described, is generally effective for killing or inactivating a broad spectrum of bacterial, fungal, and viral pathogens, including S. aureus, P. aeruginosa, E. coli, Enterococcus spp., C. difficile, and Candida Spp. The solution does not produce resistant species, making the methods desirable over the delivery of traditional antibiotics.

In another aspect, the solution of the invention is particularly suitable for use in conjunction with stem cell and growth factor therapy, including the use of genetically engineered cells and engineered tissue and allografts and organs for transplant in various treatments. Using the stabilized hypohalous acid solution of the invention to disinfect tissue before, during or after addition of cells or growth factors, maintains the viability of the cells and integrity of the growth factors, while killing the unwanted microbes.

In certain embodiments, the solution or formulation thereof is applied for the control of inflammation, including an inflammatory reaction or hyper inflammation of the skin. For example, the solution or formulation thereof may be applied for use in a method as described in US 2007/0196357 or US 2010/0285151, which are hereby incorporated by reference. In certain embodiments, the solution or composition of the invention is applied (e.g., to an effected area) for treatment of a patient having a dermatoses, atopic dermatitis, skin allergy, rosasea, psoriasis, or acne, among others. In such embodiments, the HOCl solution may be formulated as a hydrogel, for example, as described elsewhere herein.

In certain embodiments, invention is advantageous for use against microbes on surfaces because of its fast activity against bacterial spores, fungi, and other resistant microorganisms. Because of its effectiveness and the speed at which it acts, the invention meets a substantial public health need, and one that is not adequately addressed by current commonly-used antimicrobial agents. Accordingly, application of the solution to various surfaces and materials is useful to control microbial contamination, not only for the care and management of wounds, but for disinfecting hard surfaces such as medical or dental equipment, preserving and decontaminating food products, water treatment, as well as other industrial and agricultural applications. In certain embodiments, the solution or composition of the invention is applied to crops (pre- or post-harvest) or cut flowers for their preservation and/or for improving the overall quality of the product. In some embodiments, the solution is potassium based and has one or more utilities (e.g., methods of use) disclosed in PCT/US2011/43590), which is hereby incorporated by reference in its entirety.

Killing, inactivating, or otherwise reducing the active population of bacterial spores and fungi on surfaces is particularly difficult. Bacterial spores have a unique chemical composition of spore layers that make them more resistant than vegetative bacteria to the antimicrobial effects of chemical and physical agents. Likewise, the unique chemical composition of fungal cells, especially mold spores, makes them more resistant to chemical and physical agents than are other microorganisms. This resistance can be particularly troublesome when the spores or fungi are located on surfaces such as food, food contact sites, ware, hospitals and veterinary facilities, surgical implements, and hospital and surgical linens and garments.

Control of the mold Chaetomium funicola, and of bacterial spore-forming microorganisms of the Bacillus species, can be especially important during food packaging, particularly during cold or hot aseptic filling of food and beverage products. Microorganisms of the Bacillus species include Bacillus cereus, Bacillus mycoides, Bacillus subtilis, Bacillus anthracis, and Bacillus thuringiensis. These latter microorganisms share many phenotypical properties, have a high level of chromosomal sequence similarity, and are known enterotoxin producers. Bacillus cereus is one of the most problematic because Bacillus cereus has been identified as possessing increased resistance to germicidal chemicals used to decontaminate environmental surfaces.

As used herein, the term “surface” refers to both hard and soft surfaces and includes, but are not limited to, tile grout, plaster, drywall, ceramic, cement, clay, bricks, stucco, plastic, wallpaper, fabric, tiles, cement, and vinyl flooring, heating and/or cooling fins, filters, vanes, baffles, vents, crevices in walls or ceilings, paper and wood products such as lumber, paper, and cardboard, woven products such as blankets, clothing, carpets, drapery and the like. The term surface also includes human surfaces, animal surfaces, military equipment, transportation equipment, children's items, plant surfaces, seeds, outdoor surfaces, soft surfaces, air, wounds, and medical instruments, and the like.

EXAMPLES Example 1: Stabilized Hypochlorous Acid Solution

FIGS. 1A and 1B and FIGS. 2A and 2B show five cycles of AFC and pH measurements for hypochlorous acid wound treatment solutions as a function of time under two environmental conditions—COLD (C) and ROOM TEMP (R). As shown, both the pH and AFC content were not stabilized over the long term. For example, the solutions were not stabilized for more than about one week.

In an attempt to stabilize the solution, hypochlorous acid was produced by electrochemical treatment of an electrolyte comprising 4.2 g/L NaCl and 400 mg/L NaHCO3. Samples were buffered with sodium bicarbonate (NaHCO3) at pH 5.6, sodium bicarbonate (NaHCO3) in combination with disodium phosphate (Na2HPO4) at pH 6.7, or a mix of sodium bicarbonate (NaHCO3), disodium phosphate and sodium diphosphate (9 NaH2PO4: 1 Na2HPO4) at pH 5.6. Solutions were stored in the dark for 1 month in HDPE bottles prior to measuring AFC.

FIG. 3 shows the AFC drop as a function of time. The results show that solutions containing no phosphate buffer were considerably more stable (˜8% lost) when compared to Na2HPO4 buffered (˜25% lost) and 9 NaH2PO4: 1 Na2HPO4 buffered solutions (˜20% lost).

The stability of the stabilized solution as a function of time was tested. Hypochlorous acid was produced by electrochemical treatment of an electrolyte comprising 4.2 g/L NaCl and 400 mg/L NaHCO3. The solution had a pH of 5.3, an alkalinity of zero (0), and approximately 250 ppm of AFC. This solution was packaged in HDPE bottles and stored in the dark. The biocidal activity and stability of the solution as a function of time was tested by measuring pH and AFC content in unopened test bottles over a period of greater than 390 days. The results are shown in FIG. 4, showing that the solutions are stabilized, with regard to AFC content and pH for over one year.

Generally, it is assumed by NaOCl manufacturers that sodium hypochlorite solution loses approximately 20% of its titrable chlorine in the first 6 months and up to 60% within a year. One study determined that it would take 166 days for a solution of 25 mg/mL sodium hypochlorite solution at 20° C. to reach 20 mg/mL of free residual chlorine based on stability studies conducted at 50° C. and 70° C. and calculations with the Arrhenius Equation (See Nicoletti et al., “Shelf-Life of a 2.5% Sodium Hypochlorite Solution as Determined by Arrhenius Equation,” Braz Dent J (2009) 20(1): 27-31). Other studies have shown similar results (See “Product Characteristics, Sodium Hypochlorite-Stability PCH-1400-0007” PCH-1400-0007-W-EN (WW), Issue 1—May 2005, Published by Solvay Chemicals International SA). Contrary to these assumptions, the NaHCO3 buffered hypochlorous acid solution of the claimed invention retained greater than 75% of the initial level of titrable chlorine along with a pH shift of less than one unit over a period of one year.

Example 2: Biocidal Activity of Stabilized HOCl Solution

Three solutions comprising different concentrations of hypochlorous acid were produced. The first solution, containing 250 ppm hypochlorous acid, was produced via electrochemical treatment of an electrolyte comprising 4.2 g/L NaCl and 400 mg/L NaHCO3. The second solution, similarly produced via electrochemical treatment, contained 480 ppm hypochlorous acid, but no NaHCO3. The final solution contained 480 ppm hypochlorous acid, but in addition, incorporated 1000 mg/L NaHCO3.

To simulate a worst-case scenario, spores of C. difficile, a bacterial strain with high antibiotic resistance, were suspended in a highly concentrated organic medium, consisting of homogenized skin cells from pig, mucin, and bovine serum albumin. After suspending the microorganisms in the organic solution, they were inoculated onto plastic carriers, allowed to desiccate and exposed to each solution in duplicate for either 0, 4, 6, 8, 10 or 30 minutes. Due to the fact that none of the existing disinfectants have stood up to this organic load (including bleach), two different concentrations of hypochlorous acid were tested.

The results (FIG. 5) demonstrate that the solution with sodium bicarbonate possesses higher biocidal activity against C. difficile spores under high organic load conditions.

Example 3: Extended Stability Study

FIG. 6 shows the results of an extended stability study of HOCl produced by electrochemical treatment of NaHCO3 enriched NaCl solution at targeted pH 5.4, bottled in a polyethylene terephthalate (PET) container and stored at room temperature. The molar content of NaHCO3 is equivalent to 1 mole NaHCO3 per 1 mole HOCl in this formulation. Every second month 4 new samples of HOCl stabilized solution were opened over the storage time, and then reopened one month later and tested on a weekly basis. Comparison of the pH and AFC of the first opened sample with the last opened, weekly opened during that month, confirmed the stability of HOCl stabilized with sodium bicarbonate.

Example 4: Stability of HOCl with Added Sodium Bicarbonate

The stability of HOCl added to containers comprising dry sodium bicarbonate is shown in FIGS. 7A and 7B. The ionic strength or solution salinity was not affected by the addition of sodium bicarbonate. The results demonstrate that bicarbonate as a stabilizer affects both the pH and AFC stability. Without being bound to any theory, in cases where the pH is about 5.5 and the buffering ability of bicarbonate is minimal, bicarbonate may act as a stabilizer, in part, by scavenging free radicals generated by the dissociation of hypochlorous acid. The result is a minimal drop in pH and AFC over time.

Example 5: Stability of HOCl Composition for Agricultural Applications

The effect of DIC content on pH and solution stability in hypochlorous acid solutions electrochemically generated, and additionally buffered with di- and monosodium phosphate for targeted pH (which have utility for agricultural applications), is shown in FIG. 8. Compositions of hypochlorous acid with phosphate additives were tested with and without bicarbonate. The results showed better stability of hypochlorous acid in the presence of bicarbonate than with phosphates alone. Combination of DIC and phosphate buffers provided better solution stability without significantly increasing the total dissolved solids content.

Example 6: Hydrogel Formulations

A hydrogel formulation containing the stabilized hypochlorous acid solution was developed. The use of bicarbonate or dissolved inorganic carbon in accordance with the invention has only a minimal effect on the ionic strength or electroconductivity of the solution. Thus, in addition to stabilizing a HOCl solution in the pH range of about 4 to about 7.5 (e.g. about 6.0), bicarbonate or carbonate do not affect the ionic strength at the targeted pH, making it possible to use hypochlorous acid with more than 200 ppm of available free chlorine as the dispersing media in a gel formulation, especially where low ionic strength is critical for the formulation.

A low ionic strength hypochlorous acid solution (conductivity≤mS/cm (i.e., millisiemens per centimeter)), AFC=300 ppm, pH 5.3 was used for a hydrogel formulation containing 3% sodium magnesium fluorosilicate. More than 4% sodium magnesium fluorosilicate was required for the production of a hydrogel of equal viscosity made out of 8 mS/cm of HOCl with equal pH and AFC content. A lower ionic strength HOCl solution as a dispersing media allows for the addition of other buffering agents for pH optimization in the final product without negative effects on physical appearance and product stability. Due to the fact that the gelling agent is a dry buffer itself, the ability to add other buffers for pH optimization in a final product can be beneficial.

In another example, hypochlorous acid solution, AFC 350 ppm, pH 5.3, salinity 4 g/l (conductivity 8 mS/cm) was used for the production of a hydrogel containing 4% F12MgNa2Si2 (sodium magnesium fluorosilicate). The hydrogel produced had a viscosity of 330 centipoises (cP) and a pH of 8.2. To bring the pH to a “skin-friendly” range phosphoric acid was added as a buffering agent. The final hydrogel had a shift in pH over time from pH 6 to 6.8 as seen in FIG. 9. Additional buffer is limited by gel viscosity as it shifts to 220 cP with a conductivity increase to 10 mS/cm.

Low ionic strength hypochlorous acid, AFC=370 ppm, was produced by electrochemical treatment of sodium chloride substantially as described in U.S. Pat. No. 7,897,023 (which is hereby incorporated by reference in its entirety), and collected in a container with dry sodium bicarbonate, equivalent to 500 ppm of NaHCO3 as an initial form of dissolved inorganic carbon (DIC). An HOCl pH 5.2 and conductivity 0.8 mS/cm produced by this process was and used as dispersing media for a gel preparation. 3% of sodium magnesium fluorosilicate was used as a gelling agent. Hydrogel formed with a viscosity of about 10,000 cP in less than 25 minutes with an initial pH of 8.4 and a conductivity of about 1 mS/cm. Phosphoric acid was added in the amount of less than 0.25% to bring the pH of the hydrogel down to a skin-friendly range (about pH 5.5-5.8). A hydrogel with a viscosity above 2,000 cP was formed.

Claims (16)

The invention claimed is:

1. A stabilized solution or formulation thereof comprising hypochlorous acid (HOCl) and a stabilizing amount of dissolved inorganic carbon (DIC) in the form of bicarbonate or carbonate of alkaline earth metals, and having from about 0.01 to about 1.0% salinity, wherein the available free chlorine (AFC) content of the solution or formulation is from about 10 to about 5,000 parts per million (ppm), and the pH of the solution or formulation is from 4.0 to 7.0.

3. The solution or formulation of claim 1, wherein said AFC content is from about 100 to about 1000 parts per million, from about 100 to about 500 parts per million, or from about 150 to about 250 parts per million.

5. The solution or formulation of claim 1, wherein the solution contains a stabilizing amount of sodium bicarbonate.

7. The solution or formulation of claim 1, wherein the solution is prepared by electrolysis of a NaCl solution.

8. The solution or formulation of claim 7, wherein the carbonate or bicarbonate is contained within an electrolyte or added to an electrolyzed solution.

9. The solution or formulation of claim 1, wherein the HOCl is produced by electrolysis of a saline solution, and the solution or formulation has an AFC content of from 100 to 500 ppm, a salinity of from about 0.02 to about 1.0%, and from 300 to 1000 mg/L of sodium bicarbonate.

10. The solution or formulation of claim 1, wherein the solution is formulated as a gel, hydrogel, cream, or foam.

12. A method for disinfecting or cleansing a mammalian tissue, comprising, applying the solution or formulation of claim 1 to the mammalian tissue.

13. The method of claim 12, wherein the mammalian tissue is infected, has a wound or a burn, has one or more dermatoses, or has atopic dermatitis.

14. A method for disinfecting or cleansing a hard surface comprising, applying the solution or formulation of claim 1 to the hard surface.

15. The method of claim 14, wherein the hard surface comprises porcelain, steel, iron, or ceramic material.

US16/018,306 2011-03-18 2018-06-26 Stabilized hypohalous acid solutions Active US10576152B2 (en)

Priority Applications (2)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201161454383P	2011-03-18	2011-03-18
US201161526149P	2011-08-22	2011-08-22

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=46828656

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
US13/423,822 Active 2032-03-25 US8871278B2 (en)	2011-03-18	2012-03-19	Stabilized hypohalous acid solutions

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
US13/423,822 Active 2032-03-25 US8871278B2 (en)	2011-03-18	2012-03-19	Stabilized hypohalous acid solutions

Country Status (14)

Families Citing this family (33)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
US9999635B2 (en)	2007-01-16	2018-06-19	Realm Therapeutics, Inc.	Methods and compositions for treating inflammatory disorders
MX365380B (en)	2009-07-30	2019-05-31	Invekra S A P I De C V	Hydrogel formulation comprising oxidative reductive potential water.
CA2860423A1 (en)	2012-01-06	2013-07-11	Puricore, Inc.	Electrochemically treated nutrient solutions
US20140328945A1 (en) *	2013-05-03	2014-11-06	Aquaxo, Inc.	METHOD FOR STABILIZING AN ELECTROCHEMICALLY GENERATED SANITIZING SOLUTION HAVING A PREDETERMINED LEVEL OF FREE AVAILABLE CHLORINE AND pH
CN105636910A (en) *	2013-08-30	2016-06-01	爱博思株式会社	Cleaning solution and manufacturing method therefor
WO2015048537A1 (en) *	2013-09-27	2015-04-02	R-Hangel, LLC	Activated solutions for water treatment
CN107206019B (en) *	2014-12-16	2021-09-24	优格美国有限公司	Hypochlorous acid formulations and methods for treating skin conditions
US10094030B2 (en)	2015-02-03	2018-10-09	Tipul Biotechnology, LLC	Devices and methods for electrolytic production of disinfectant solution from salt solution in a container
CN106260992B (en) *	2015-06-09	2020-02-18	海南椰国食品有限公司	A food containing acidic and/or alkaline coconut
CN106267304B (en) *	2015-06-09	2019-10-18	海南光宇生物科技有限公司	Biological cellulose gel film and medical dressing prepared therefrom with acid-base property
WO2018109169A1 (en)	2016-12-15	2018-06-21	Adept Water Technologies A/S	Device for producing aqueous liquid having free available chlorine (fac)
CN110952108A (en) *	2019-12-23	2020-04-03	北大荒绿源食品加工有限公司	Production method for improving stability of hypochlorous acid solution
TWI727680B (en) *	2020-02-27	2021-05-11	超水國際股份有限公司	Hypochlorous acid disinfectant and its production method
CN111481723B (en) *	2020-04-17	2022-02-01	重庆有艾生物科技有限公司	Integrated technology and method for dynamically disinfecting air in gathering place by using weak-acid hypochlorous acid disinfectant
CN111437434B (en) *	2020-05-09	2022-01-28	娄长伟	Hypochlorous acid liquid dressing and preparation method thereof
CN112831797A (en) *	2020-12-31	2021-05-25	平湖爱之馨环保科技有限公司	Composite electrolytic salt and electrolytic mother liquor prepared by using same
WO2022251050A1 (en) *	2021-05-24	2022-12-01	De Nora Water Technologies, LLC	Production of aqueous hypochlorous acid through the electrolysis of ph modified brines

Citations (93)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
JPS503419A (en)	1973-04-30	1975-01-14
US4104190A (en)	1976-03-23	1978-08-01	Minnesota Mining And Manufacturing Company	Generation of chlorine dioxide for disinfection and sterilization
US4507285A (en)	1982-04-10	1985-03-26	Kuehne Friedrich Wilhelm	Stabilized activated oxygen and pharmaceutical compositions containing said stabilized activated oxygen
WO1996002271A1 (en)	1994-07-15	1996-02-01	Medical Discoveries, Inc.	Electrically hydrolyzed salines as in vivo microbicides for the treatment of cardiomyopathy and multiple sclerosis
WO1999034652A1 (en)	1997-12-30	1999-07-08	Radical Waters Ip (Pty) Ltd.	An irrigating medium for root canals
US6022840A (en)	1998-02-25	2000-02-08	Reckitt & Colman Inc.	Aqueous cleaning compositions containing 2-ethylhexyl sulfate and C8 -C10 alkyldimethylamine oxide for removing soap scum
US6036789A (en)	1998-02-25	2000-03-14	Reckitt & Colman Inc.	Aqueous cleaning compositions containing 2-ethylhexyl sulfate and optionally myristyldimethylamine oxide for removing soap scum
US20020071805A1 (en)	1999-12-15	2002-06-13	Khan Mohammed N. I.	Method and means of preparing chlorinated bicarbonates and carbonates of calcium and alkali metals
US6426066B1 (en)	2000-01-12	2002-07-30	California Pacific Labs, Inc.	Use of physiologically balanced, ionized, acidic solution in wound healing
US20020160053A1 (en)	1999-11-17	2002-10-31	Naoki Yahagi	Solution for promoting growth of tissue cells at wound sites and production process therefor
WO2003040038A2 (en)	2001-10-26	2003-05-15	Zodiac Pool Care, Inc.	Method and apparatus for purifying water
US20030109398A1 (en)	2000-03-10	2003-06-12	Tetsuya Yoneda	Cleaning solution, and method and apparatus for cleaning using the same
EP1323678A1 (en)	2001-12-25	2003-07-02	SANYO ELECTRIC Co., Ltd.	Water treating apparatus
US20030146108A1 (en)	2001-12-28	2003-08-07	Omega Co., Ltd.	Method of producing washing, cleaning and sterilizing solution and system using such solution
US20030185704A1 (en)	2000-01-12	2003-10-02	Suzanne Bernard	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US20040137078A1 (en)	2000-01-12	2004-07-15	Ramin Najafi	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US20040256330A1 (en)	2003-05-12	2004-12-23	Tatsuo Okazaki	Method of preparing sterile water containing hypochlorous or chlorous acid, package of sterile source materials, sterile water preparation kit, method and apparatus for spatial sterilization
US20050139808A1 (en)	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and process for producing same
US20050142157A1 (en)	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and methods of using the same
US20050196462A1 (en)	2003-12-30	2005-09-08	Oculus Innovative Sciences, Inc.	Topical formulation containing oxidative reductive potential water solution and method for using same
WO2006014223A1 (en)	2004-07-06	2006-02-09	Johnsondiversey, Inc.	Stable nonaqueous bleaching detergent composition dispersion
WO2006057311A1 (en)	2004-11-24	2006-06-01	Maruishi Pharmaceutical Co., Ltd.	Hypochlorous acid based sterilizer composition
US20060235350A1 (en)	2005-03-23	2006-10-19	Oculus Innovative Sciences, Inc.	Method of treating skin ulcers using oxidative reductive potential water solution
US20060253060A1 (en)	2005-05-02	2006-11-09	Oculus Innovative Sciences, Inc.	Method of using oxidative reductive potential water solution in dental applications
EP1550468B1 (en)	2004-01-05	2007-04-04	Laboratoires Rivadis	Process for the production of a solution comprising sodium chloride and sodium hypochloride
WO2007070637A2 (en)	2005-12-13	2007-06-21	Puricore, Inc.	Method of treating open wounds using hypochlorous acid
WO2007072697A1 (en)	2005-12-20	2007-06-28	Noguchi Dental Medical Research Institute	Bactericidal water, method of producing the same and apparatus for producing the same
WO2007075865A2 (en)	2005-12-20	2007-07-05	Ceramatec, Inc.	Electrolytic process to produce sodium hypochlorite using sodium ion conductive ceramic membranes
US20070196357A1 (en)	2006-01-20	2007-08-23	Oculus Innovative Sciences, Inc.	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
US20080014289A1 (en)	2006-07-12	2008-01-17	Jianping Li	Vehicle and method for treating and preventing acne vulgaris and exfoliating the skin hypohalous acids
WO2008089268A2 (en)	2007-01-16	2008-07-24	Puricore, Inc.	Methods and compositions for treating conditions associated with infection and/or inflammation
WO2008089893A1 (en)	2007-01-12	2008-07-31	Gb International Limited	Method and composition for treating starch-based grain products during starch extraction and modification
WO2008112940A1 (en)	2007-03-13	2008-09-18	Oculus Innovative Sciences, Inc.	Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same
JP2008255310A (en)	2007-04-02	2008-10-23	Raku:Kk	Detergent composition to use exclusively for jet nozzle in warm water toilet seat
US20090110749A1 (en)	2007-10-30	2009-04-30	Medical Management Research, Inc.	Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic
JP2009161453A (en)	2007-12-28	2009-07-23	Earth Chem Corp Ltd	Gel-like composition against harmful insect and gel-like spray product against harmful insect
WO2009098873A1 (en)	2008-02-08	2009-08-13	Noguchi Dental Medical Research Institute	Sterilized water, and method and device for producing the water
WO2009098870A1 (en)	2008-02-08	2009-08-13	Noguchi Dental Medical Research Institute	Dental sterilizing water, method for producing the water, and device for producing the water
US20090221989A1 (en)	2005-09-21	2009-09-03	Novabay Pharmaceuticals Inc	System and method for the prevention and treatment of bacterial and fungal infections including urinary tract infections (uti) using a hypohalous acid composition
WO2010027825A2 (en)	2008-08-25	2010-03-11	Ceramatec, Inc.	Methods for producing sodium hypochlorite with a three-comportment apparatus containing an acidic anolyte
WO2010090361A1 (en)	2009-02-05	2010-08-12	Kim Chil-Young	Food packaging method using sterilizing water containing residual chlorine produced through eletrolysis
US20100310672A1 (en)	2007-05-15	2010-12-09	Alfons Beltrup	Disinfectant based on aqueous; hypochlorous acid (hoci)-containing solutions; method for the production thereof and use thereof
WO2010146460A1 (en)	2009-06-17	2010-12-23	Apr Nanotechnologies S.A.	Methods of treating outer eye disorders using high orp acid water and compositions thereof
US20110020474A1 (en)	2009-07-27	2011-01-27	Novabay Pharmaceuticals, Inc.	Methods of Treating Infections of the Nail or Skin Using Hypohalite
WO2011014809A1 (en)	2009-07-30	2011-02-03	Oculus Innovative Sciences, Inc.	Hydrogel formulation comprising oxidative reductive potential water
WO2011058764A1 (en)	2009-11-16	2011-05-19	パーフェクトペリオ株式会社	Gargle preparation, and process and apparatus for production of same
US20120024028A1 (en)	2010-07-09	2012-02-02	Puricore, Inc.	Electrochemically treated nutrient solutions

Family Cites Families (11)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
JP2004204328A (en) *	2002-12-26	2004-07-22	Takatoshi Nakajima	Method of producing hypochlorous acid solution, and utilizing method thereof
WO2008118957A2 (en)	2007-03-26	2008-10-02	The Government Of U.S.A As Represented By The Secretary Of The Department Of Health & Human Services	Methods for modulating embryonic stem cell differentiation
US20080311227A1 (en) *	2007-06-18	2008-12-18	Wd-40 Company	Long-lasting mildew stain remover and method for making same
JP5879259B2 (en) *	2009-05-22	2016-03-08	サバンベンチャーズピーティーワイリミテッド	Sterilization aerosol and method of using the sterilization aerosol

2012

2012-03-19 WO PCT/US2012/029650 patent/WO2012129161A2/en active Application Filing
2012-03-19 BR BR112013023816A patent/BR112013023816A2/en not_active Application Discontinuation

2014
2016
2018

Patent Citations (112)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
JPS503419A (en)	1973-04-30	1975-01-14
US4104190A (en)	1976-03-23	1978-08-01	Minnesota Mining And Manufacturing Company	Generation of chlorine dioxide for disinfection and sterilization
US4507285A (en)	1982-04-10	1985-03-26	Kuehne Friedrich Wilhelm	Stabilized activated oxygen and pharmaceutical compositions containing said stabilized activated oxygen
WO1996002271A1 (en)	1994-07-15	1996-02-01	Medical Discoveries, Inc.	Electrically hydrolyzed salines as in vivo microbicides for the treatment of cardiomyopathy and multiple sclerosis
WO1999034652A1 (en)	1997-12-30	1999-07-08	Radical Waters Ip (Pty) Ltd.	An irrigating medium for root canals
US6022840A (en)	1998-02-25	2000-02-08	Reckitt & Colman Inc.	Aqueous cleaning compositions containing 2-ethylhexyl sulfate and C8 -C10 alkyldimethylamine oxide for removing soap scum
US6036789A (en)	1998-02-25	2000-03-14	Reckitt & Colman Inc.	Aqueous cleaning compositions containing 2-ethylhexyl sulfate and optionally myristyldimethylamine oxide for removing soap scum
US20090092685A1 (en)	1999-08-23	2009-04-09	Puricore International Limited	Wound and ulcer treatment with super-oxidized water
EP1259114B1 (en)	1999-10-21	2004-12-29	AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A.	A topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
US20020160053A1 (en)	1999-11-17	2002-10-31	Naoki Yahagi	Solution for promoting growth of tissue cells at wound sites and production process therefor
US20020071805A1 (en)	1999-12-15	2002-06-13	Khan Mohammed N. I.	Method and means of preparing chlorinated bicarbonates and carbonates of calcium and alkali metals
US20040137078A1 (en)	2000-01-12	2004-07-15	Ramin Najafi	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US20030185704A1 (en)	2000-01-12	2003-10-02	Suzanne Bernard	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US6426066B1 (en)	2000-01-12	2002-07-30	California Pacific Labs, Inc.	Use of physiologically balanced, ionized, acidic solution in wound healing
US7393522B2 (en)	2000-01-12	2008-07-01	Novabay Pharmaceuticals, Inc.	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US20030109398A1 (en)	2000-03-10	2003-06-12	Tetsuya Yoneda	Cleaning solution, and method and apparatus for cleaning using the same
WO2003040038A2 (en)	2001-10-26	2003-05-15	Zodiac Pool Care, Inc.	Method and apparatus for purifying water
EP1323678A1 (en)	2001-12-25	2003-07-02	SANYO ELECTRIC Co., Ltd.	Water treating apparatus
US20030146108A1 (en)	2001-12-28	2003-08-07	Omega Co., Ltd.	Method of producing washing, cleaning and sterilizing solution and system using such solution
US6927192B2 (en)	2002-02-15	2005-08-09	Regents Of The University Of Minnesota	Process to improve the quality of grains and seeds
US20040256330A1 (en)	2003-05-12	2004-12-23	Tatsuo Okazaki	Method of preparing sterile water containing hypochlorous or chlorous acid, package of sterile source materials, sterile water preparation kit, method and apparatus for spatial sterilization
US20050139808A1 (en)	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and process for producing same
US20050142157A1 (en)	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and methods of using the same
US20050196462A1 (en)	2003-12-30	2005-09-08	Oculus Innovative Sciences, Inc.	Topical formulation containing oxidative reductive potential water solution and method for using same
EP1550468B1 (en)	2004-01-05	2007-04-04	Laboratoires Rivadis	Process for the production of a solution comprising sodium chloride and sodium hypochloride
US7527783B2 (en)	2004-03-23	2009-05-05	The Clorox Company	Methods for deactivating allergens and preventing disease
WO2006014223A1 (en)	2004-07-06	2006-02-09	Johnsondiversey, Inc.	Stable nonaqueous bleaching detergent composition dispersion
WO2006057311A1 (en)	2004-11-24	2006-06-01	Maruishi Pharmaceutical Co., Ltd.	Hypochlorous acid based sterilizer composition
US20060241546A1 (en)	2005-03-23	2006-10-26	Oculus Innovative Sciences, Inc.	Method of treating second and third degree burns using oxidative reductive potential water solution
US20060235350A1 (en)	2005-03-23	2006-10-19	Oculus Innovative Sciences, Inc.	Method of treating skin ulcers using oxidative reductive potential water solution
US20060253060A1 (en)	2005-05-02	2006-11-09	Oculus Innovative Sciences, Inc.	Method of using oxidative reductive potential water solution in dental applications
US20090221989A1 (en)	2005-09-21	2009-09-03	Novabay Pharmaceuticals Inc	System and method for the prevention and treatment of bacterial and fungal infections including urinary tract infections (uti) using a hypohalous acid composition
WO2007070637A2 (en)	2005-12-13	2007-06-21	Puricore, Inc.	Method of treating open wounds using hypochlorous acid
WO2007072697A1 (en)	2005-12-20	2007-06-28	Noguchi Dental Medical Research Institute	Bactericidal water, method of producing the same and apparatus for producing the same
WO2007075865A2 (en)	2005-12-20	2007-07-05	Ceramatec, Inc.	Electrolytic process to produce sodium hypochlorite using sodium ion conductive ceramic membranes
US20100092399A1 (en)	2006-01-20	2010-04-15	Oculus Innovative Sciences, Inc.	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
US20070196434A1 (en)	2006-01-20	2007-08-23	Oculus Innovative Sciences, Inc.	Methods of preventing or treating sinusitis with oxidative reductive potential water solution
US8147444B2 (en)	2006-01-20	2012-04-03	Oculus Innovative Sciences, Inc.	Methods of treating or preventing peritonitis with oxidative reductive potential water solution
US20070196357A1 (en)	2006-01-20	2007-08-23	Oculus Innovative Sciences, Inc.	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
US20080014289A1 (en)	2006-07-12	2008-01-17	Jianping Li	Vehicle and method for treating and preventing acne vulgaris and exfoliating the skin hypohalous acids
WO2008089893A1 (en)	2007-01-12	2008-07-31	Gb International Limited	Method and composition for treating starch-based grain products during starch extraction and modification
US20100285151A1 (en)	2007-01-16	2010-11-11	Puricore, Inc.	Methods and compositions for treating conditions associated with infection and/or inflammation
WO2008089268A2 (en)	2007-01-16	2008-07-24	Puricore, Inc.	Methods and compositions for treating conditions associated with infection and/or inflammation
WO2008112940A1 (en)	2007-03-13	2008-09-18	Oculus Innovative Sciences, Inc.	Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same
JP2008255310A (en)	2007-04-02	2008-10-23	Raku:Kk	Detergent composition to use exclusively for jet nozzle in warm water toilet seat
EP2146580B1 (en)	2007-05-15	2011-10-19	Actides Gmbh	USE OF A DISINFECTANT BASED ON AQUEOUS, HYPOCHLOROUS ACID (HOCl)-CONTAINING SOLUTIONS
US20100310672A1 (en)	2007-05-15	2010-12-09	Alfons Beltrup	Disinfectant based on aqueous; hypochlorous acid (hoci)-containing solutions; method for the production thereof and use thereof
US20090110749A1 (en)	2007-10-30	2009-04-30	Medical Management Research, Inc.	Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic
JP2009161453A (en)	2007-12-28	2009-07-23	Earth Chem Corp Ltd	Gel-like composition against harmful insect and gel-like spray product against harmful insect
EP2241322A1 (en)	2008-02-08	2010-10-20	Noguchi Dental Medical Research Institute	Dental sterilizing water, method for producing the water, and device for producing the water
WO2009098870A1 (en)	2008-02-08	2009-08-13	Noguchi Dental Medical Research Institute	Dental sterilizing water, method for producing the water, and device for producing the water
WO2009098873A1 (en)	2008-02-08	2009-08-13	Noguchi Dental Medical Research Institute	Sterilized water, and method and device for producing the water
WO2010027825A2 (en)	2008-08-25	2010-03-11	Ceramatec, Inc.	Methods for producing sodium hypochlorite with a three-comportment apparatus containing an acidic anolyte
WO2010090361A1 (en)	2009-02-05	2010-08-12	Kim Chil-Young	Food packaging method using sterilizing water containing residual chlorine produced through eletrolysis
WO2010146460A1 (en)	2009-06-17	2010-12-23	Apr Nanotechnologies S.A.	Methods of treating outer eye disorders using high orp acid water and compositions thereof
US20110020474A1 (en)	2009-07-27	2011-01-27	Novabay Pharmaceuticals, Inc.	Methods of Treating Infections of the Nail or Skin Using Hypohalite
WO2011014809A1 (en)	2009-07-30	2011-02-03	Oculus Innovative Sciences, Inc.	Hydrogel formulation comprising oxidative reductive potential water
US20120164235A1 (en)	2009-07-30	2012-06-28	Oculus Innovative Sciences, Inc.	Hydrogel formulation comprising oxidative reductive potential water
WO2011058764A1 (en)	2009-11-16	2011-05-19	パーフェクトペリオ株式会社	Gargle preparation, and process and apparatus for production of same
US20120024028A1 (en)	2010-07-09	2012-02-02	Puricore, Inc.	Electrochemically treated nutrient solutions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party Title

Chlorination Chemistry, Mountain Empire Community College, http://water.me.vccs.edu/concepts/chlorchemistry.html (Nov. 16, 2004).

International Search Report and Written Opinion from PCT Application No. PCT/US2012/029650, 10 pages (dated Jun. 19, 2012).

MIT OpenCourseWare, 3.091SC Introduction to Solid State Chemistry, http://ocw.mit.edu (Fall, 2009).

Also Published As

Publication number

Publication date

Legal Events

Date	Code	Title	Description
2018-06-26	FEPP	Fee payment procedure	Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY
2018-07-11	FEPP	Fee payment procedure	Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY
2019-01-31	AS	Assignment	Owner name: REALM THERAPEUTICS, INC., PENNSYLVANIA Free format text: CHANGE OF NAME;ASSIGNOR:PURICORE, INC.;REEL/FRAME:048204/0629 Effective date: 20161207
2019-04-25	STPP	Information on status: patent application and granting procedure in general	Free format text: NON FINAL ACTION MAILED
2019-06-07	AS	Assignment	Owner name: URGO US, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REALM THERAPEUTICS, INC.;REEL/FRAME:049405/0191 Effective date: 20190328
2019-09-05	STPP	Information on status: patent application and granting procedure in general	Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER
2019-10-21	STPP	Information on status: patent application and granting procedure in general	Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS
2020-01-21	FEPP	Fee payment procedure	Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY
2020-01-28	STPP	Information on status: patent application and granting procedure in general	Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED
2020-02-12	STCF	Information on status: patent grant	Free format text: PATENTED CASE

stabilized solution or formulation, its method of preparation, methods of application and uses

Info

Publication number BR112013023816A2 BR112013023816A BR112013023816A BR112013023816A2 BR 112013023816 A2 BR112013023816 A2 BR 112013023816A2 BR 112013023816 A BR112013023816 A BR 112013023816A BR 112013023816 A BR112013023816 A BR 112013023816A BR 112013023816 A2 BR112013023816 A2 BR 112013023816A2 Authority Prior art keywords Prior art date

Application number

Other languages

Inventor

Martyn James Rogers

Svetlana Panicheva

Original Assignee

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Filing date

Publication date

Priority claimed from US201161454383P external-priority

2012-03-19 Application filed by Puricore Inc filed Critical Puricore Inc

2016-12-13 Publication of BR112013023816A2 publication Critical patent/BR112013023816A2/en

Classifications

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/02—Inorganic compounds

A—HUMAN NECESSITIES
A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N25/22—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients

A—HUMAN NECESSITIES
A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds

A—HUMAN NECESSITIES
A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
A23L3/358—Inorganic compounds

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
A61K33/10—Carbonates; Bicarbonates

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
A61K33/12—Magnesium silicate

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/42—Phosphorus; Compounds thereof

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders
A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/02—Local antiseptics

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/04—Antibacterial agents

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P37/00—Drugs for immunological or allergic disorders
A61P37/08—Antiallergic agents

C—CHEMISTRY; METALLURGY
C01—INORGANIC CHEMISTRY
C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
C01B11/00—Oxides or oxyacids of halogens; Salts thereof
C01B11/04—Hypochlorous acid

BR112013023816A 2011-03-18 2012-03-19 stabilized solution or formulation, its method of preparation, methods of application and uses BR112013023816A2 (en)

Applications Claiming Priority (3)

Publications (1)

Family

ID=46828656

Family Applications (1)

Country Status (14)

Families Citing this family (33)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
US9999635B2 (en)	2007-01-16	2018-06-19	Realm Therapeutics, Inc.	Methods and compositions for treating inflammatory disorders
MX365380B (en)	2009-07-30	2019-05-31	Invekra S A P I De C V	Hydrogel formulation comprising oxidative reductive potential water.
WO2014153293A1 (en) *	2013-03-18	2014-09-25	Aqua Access Llc	Methods and apparatuses related to treatment in milking facilities
CN105636910A (en) *	2013-08-30	2016-06-01	爱博思株式会社	Cleaning solution and manufacturing method therefor
WO2015048537A1 (en) *	2013-09-27	2015-04-02	R-Hangel, LLC	Activated solutions for water treatment
CN107206019B (en) *	2014-12-16	2021-09-24	优格美国有限公司	Hypochlorous acid formulations and methods for treating skin conditions
US10094030B2 (en)	2015-02-03	2018-10-09	Tipul Biotechnology, LLC	Devices and methods for electrolytic production of disinfectant solution from salt solution in a container
CN106260992B (en) *	2015-06-09	2020-02-18	海南椰国食品有限公司	A food containing acidic and/or alkaline coconut
CN106267304B (en) *	2015-06-09	2019-10-18	海南光宇生物科技有限公司	Biological cellulose gel film and medical dressing prepared therefrom with acid-base property
WO2018109169A1 (en)	2016-12-15	2018-06-21	Adept Water Technologies A/S	Device for producing aqueous liquid having free available chlorine (fac)
CN110952108A (en) *	2019-12-23	2020-04-03	北大荒绿源食品加工有限公司	Production method for improving stability of hypochlorous acid solution
TWI727680B (en) *	2020-02-27	2021-05-11	超水國際股份有限公司	Hypochlorous acid disinfectant and its production method
CN111481723B (en) *	2020-04-17	2022-02-01	重庆有艾生物科技有限公司	Integrated technology and method for dynamically disinfecting air in gathering place by using weak-acid hypochlorous acid disinfectant
CN111437434B (en) *	2020-05-09	2022-01-28	娄长伟	Hypochlorous acid liquid dressing and preparation method thereof
CN112831797A (en) *	2020-12-31	2021-05-25	平湖爱之馨环保科技有限公司	Composite electrolytic salt and electrolytic mother liquor prepared by using same
CN113180056B (en) *	2021-04-30	2022-04-19	浙江德茵菲科生物科技股份有限公司	Hypochlorous acid disinfectant
WO2022251050A1 (en) *	2021-05-24	2022-12-01	De Nora Water Technologies, LLC	Production of aqueous hypochlorous acid through the electrolysis of ph modified brines

Family Cites Families (104)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
US4048300A (en) *	1973-01-11	1977-09-13	Colgate-Palmolive Company	Dental preparation containing materials having calcium and phosphate components
DE3213389A1 (en) *	1982-04-10	1983-10-20	Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne	STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN
US5622848A (en)	1990-05-23	1997-04-22	Medical Discoveries, Inc.	Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood
JPH07509536A (en)	1992-04-03	1995-10-19
US6149821A (en)	1998-05-15	2000-11-21	Advanced Water Technology, Inc.	Balanced water purification system
DE60036582T2 (en)	1999-08-06	2008-06-26	Puricore International Ltd.	Electrochemical treatment of an aqueous solution
US6333054B1 (en) *	1999-10-21	2001-12-25	Amuchina S.P.A.	Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
JP2001139477A (en)	1999-11-17	2001-05-22	Coherent Technology:Kk	Tissue cell growth-promoting liquid for wounded part
US20020071805A1 (en)	1999-12-15	2002-06-13	Khan Mohammed N. I.	Method and means of preparing chlorinated bicarbonates and carbonates of calcium and alkali metals
US6426066B1 (en)	2000-01-12	2002-07-30	California Pacific Labs, Inc.	Use of physiologically balanced, ionized, acidic solution in wound healing
US7393522B2 (en) *	2000-01-12	2008-07-01	Novabay Pharmaceuticals, Inc.	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US20030185704A1 (en)	2000-01-12	2003-10-02	Suzanne Bernard	Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
US7015184B2 (en)	2000-03-10	2006-03-21	Sharp Kabushiki Kaisha	Cleaning solution, and method and apparatus for cleaning using the same
US6761827B2 (en)	2001-10-26	2004-07-13	Zodiac Pool Care, Inc.	Method and apparatus for purifying water
JP3768160B2 (en)	2001-12-25	2006-04-19	三洋電機株式会社	Water treatment equipment
JP4197893B2 (en)	2001-12-28	2008-12-17	株式会社オメガ	Method and apparatus for producing washing / cleaning sterilizing water
JP2003251355A (en)	2001-12-28	2003-09-09	Omega:Kk	Method for cleaning and sterilizing service water or the like and device therefor
US6927192B2 (en)	2002-02-15	2005-08-09	Regents Of The University Of Minnesota	Process to improve the quality of grains and seeds
JP3981289B2 (en) *	2002-03-29	2007-09-26	株式会社ダイゾー	Foamable aerosol composition
US6825159B2 (en)	2002-10-15	2004-11-30	Ecolab, Inc.	Alkaline cleaning composition with increased chlorine stability
JP2004204328A (en) *	2002-12-26	2004-07-22	Takatoshi Nakajima	Method of producing hypochlorous acid solution, and utilizing method thereof
US20040256330A1 (en) *	2003-05-12	2004-12-23	Tatsuo Okazaki	Method of preparing sterile water containing hypochlorous or chlorous acid, package of sterile source materials, sterile water preparation kit, method and apparatus for spatial sterilization
JP2005000238A (en) *	2003-06-09	2005-01-06	Hiromaito Co Ltd	Method for manufacturing vessel filled with disinfectant aqueous solution
US9168318B2 (en)	2003-12-30	2015-10-27	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and methods of using the same
US20050196462A1 (en)	2003-12-30	2005-09-08	Oculus Innovative Sciences, Inc.	Topical formulation containing oxidative reductive potential water solution and method for using same
US20050139808A1 (en) *	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and process for producing same
JP2005245964A (en) *	2004-03-08	2005-09-15	Hiromaito Co Ltd	Container to be filled with aqueous solution of microbicide
US7527783B2 (en) *	2004-03-23	2009-05-05	The Clorox Company	Methods for deactivating allergens and preventing disease
WO2006057311A1 (en)	2004-11-24	2006-06-01	Maruishi Pharmaceutical Co., Ltd.	Hypochlorous acid based sterilizer composition
KR101523091B1 (en)	2005-03-23	2015-05-26	오클루스 이노바티브 사이언시즈 인코포레이티드	Method of treating skin ulcers using oxidative reductive potential water solution
EP1896043B1 (en)	2005-05-02	2018-08-29	Sonoma Pharmaceuticals, Inc.	Method of using oxidative reductive potential water solution in dental applications
JP2009517335A (en)	2005-09-21	2009-04-30	ノバベイ・ファーマシューティカルズ・インコーポレイテッド	System and method for prevention and treatment of bacterial and fungal infections including urinary tract infection (UTI) using hypohalous acid composition
JPWO2007072697A1 (en)	2005-12-20	2009-05-28	野口歯科医学研究所株式会社	Bactericidal water, method for producing the same, and production device
US8268159B2 (en)	2005-12-20	2012-09-18	Ceramatec, Inc.	Electrolytic process to produce sodium hypochlorite using sodium ion conductive ceramic membranes
CA2637178C (en)	2006-01-20	2018-09-04	Oculus Innovative Sciences, Inc.	Methods of preventing or treating sinusitis with oxidative reductive potential water solution
WO2007092180A2 (en)	2006-01-27	2007-08-16	University Of Florida Research Foundation, Inc.	Materials and methods for providing oxygen to improve seed germination and plant growth
US20080014289A1 (en) *	2006-07-12	2008-01-17	Jianping Li	Vehicle and method for treating and preventing acne vulgaris and exfoliating the skin hypohalous acids
WO2008040020A2 (en)	2006-09-28	2008-04-03	Puricore, Inc.	Apparatus and method for wound, cavity, and bone treatment
US20100003342A1 (en)	2006-12-11	2010-01-07	Ideo Co., Ltd.	Aqueous solution and method of prolonging life of residual chlorine in aqueous solution
WO2008089893A1 (en)	2007-01-12	2008-07-31	Gb International Limited	Method and composition for treating starch-based grain products during starch extraction and modification
US8877257B2 (en)	2007-01-16	2014-11-04	Puricore, Inc.	Methods and compositions for treating conditions associated with infection and/or inflammation
EP2136819A1 (en)	2007-03-13	2009-12-30	Oculus Innovative Sciences, Inc.	Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same
WO2008118957A2 (en)	2007-03-26	2008-10-02	The Government Of U.S.A As Represented By The Secretary Of The Department Of Health & Human Services	Methods for modulating embryonic stem cell differentiation
JP2008255310A (en) *	2007-04-02	2008-10-23	Raku:Kk	Detergent composition to use exclusively for jet nozzle in warm water toilet seat
DE102007022994A1 (en)	2007-05-15	2008-11-20	Actides Gmbh	Disinfectants based on electrochemically activated water / electrolyte solutions, process for their preparation and use thereof
US20080311227A1 (en) *	2007-06-18	2008-12-18	Wd-40 Company	Long-lasting mildew stain remover and method for making same
US20090110749A1 (en)	2007-10-30	2009-04-30	Medical Management Research, Inc.	Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic
JP4369530B2 (en)	2008-02-08	2009-11-25	野口歯科医学研究所株式会社	Dental sterilizing water, method for producing the same, and device for producing the same
JPWO2009098873A1 (en) *	2008-02-08	2011-05-26	パーフェクトペリオ株式会社	Sterilized water, method for producing the same, and apparatus for producing the same
WO2010027819A2 (en)	2008-08-25	2010-03-11	Ceramatec, Inc	Methods for producing sodium hypochlorite with a three-compartment apparatus containing a basic anolyte
WO2010090361A1 (en)	2009-02-05	2010-08-12	Kim Chil-Young	Food packaging method using sterilizing water containing residual chlorine produced through eletrolysis
JP5879259B2 (en) *	2009-05-22	2016-03-08	サバンベンチャーズピーティーワイリミテッド	Sterilization aerosol and method of using the sterilization aerosol
CN102480972B (en) *	2009-06-15	2014-12-10	奥古露丝创新科学公司	Solution containing hypochlorous acid and methods of using same
EP2442818B1 (en)	2009-06-17	2015-07-22	APR Nanotechnologies S.A.	Methods of treating outer eye disorders using high orp acid water and compositions thereof
WO2011014460A1 (en)	2009-07-27	2011-02-03	Novabay Pharmaceuticals, Inc.	Methods of treating infections of the nail or skin using hypohalite
MX365380B (en)	2009-07-30	2019-05-31	Invekra S A P I De C V	Hydrogel formulation comprising oxidative reductive potential water.
JP2013028539A (en)	2009-11-16	2013-02-07	Perfect Perio Co Ltd	Gargle preparation, and process and apparatus for production of same
EP2450313A1 (en)	2010-11-09	2012-05-09	Caliopa AG	Method for producing an electrochemically activated solution by means of electrolysis
WO2012150477A2 (en)	2010-12-16	2012-11-08	Apr Nanotechnologies S.A.	Medical uses of nanoclustered water
JP3166522U (en) *	2010-12-24	2011-03-10	ナナイロ株式会社	Nebulizer for sterilization and deodorization

2012

2012-03-19 WO PCT/US2012/029650 patent/WO2012129161A2/en active Application Filing
2012-03-19 BR BR112013023816A patent/BR112013023816A2/en not_active Application Discontinuation

2014
2016

2016-06-16 US US15/184,207 patent/US10034942B2/en active Active

2018

2018-06-26 US US16/018,306 patent/US10576152B2/en active Active

Also Published As

Publication number

Publication date

Legal Events

Date	Code	Title	Description
2018-04-03	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2020-05-05	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-11-03	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-01-19	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2021-08-24	B25G	Requested change of headquarter approved	Owner name: REALM THERAPEUTICS, INC. (US)
2021-09-14	B25A	Requested transfer of rights approved	Owner name: URGO US, INC. (US)

Publication	Publication Date	Title
BR112015003376A8 (en)	2018-01-23	pharmaceutically acceptable compound or salt thereof, pharmaceutical composition and uses of efficient amount of pharmaceutically acceptable compound or salt thereof or pharmaceutical composition
BR112014028368A2 (en)	2017-11-14	method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation
BR112015002755A2 (en)	2017-07-04	hyaluronic acid derivative, preparation method of hyaluronic acid derivative, modification method of hyaluronic acid derivative and use of derivatives
BR112013029203A2 (en)	2016-08-09	method for preparing one or more human milk oligosaccharides, and use of human milk oligosaccharides
BR112013022556A8 (en)	2018-01-16	semi-solid aqueous pharmaceutical composition containing tapentadol, its use and use of tapentadol

Stabilized hypohalous acid solutions (US10576152B2)

Info

Links

Images

Classifications

Abstract

Description

Claims (16)

Priority Applications (2)

Applications Claiming Priority (6)

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=46828656

Family Applications (5)

Family Applications Before (4)

Country Status (14)

Families Citing this family (33)

Citations (93)

Family Cites Families (11)

Patent Citations (112)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events

Info

Links

Classifications

Applications Claiming Priority (3)

Publications (1)

Family

ID=46828656

Family Applications (1)

Country Status (14)

Families Citing this family (33)

Family Cites Families (104)

Also Published As

Similar Documents

Legal Events